Wellington Leads Genticel Financing

Wellington Partners has led a 18.2 million euros series C financing round at Toulouse/France-based therapeutic HPV- vaccine developer Genticel. Wellington Partners committed 4 million euros to this financing. The remaining 14.2 million euros were provided by the existing shareholders including EdRIP, IDInvest, InnoBio, IRDI and Amundi.

24 April 2013•3 mins read
Feature image
LinkedInXEmail
LinkedInXEmail